Evidence map›Paper›PMID 38555379›Full record

ArticleNPJ vaccines2024

Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform.

Marcal Yll-Pico, Yoonsuh Park, Joy Martinez, Angelina Iniguez, Mindy Kha, Taehyun Kim, Leonard Medrano, Vu H Nguyen, Teodora Kaltcheva, Shannon Dempsey and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. A vaccine against cytomegalovirus: how close are we?The Journal of clinical investigation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Marcal Yll-Pico *Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA. myllpico@coh.org.ORCID http://orcid.org/0000-0002-7030-3360
Yoonsuh Park *Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Joy MartinezDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Angelina IniguezDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Mindy KhaDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Taehyun KimDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Leonard MedranoDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Vu H NguyenDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Teodora KaltchevaDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Shannon DempseyDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.
Flavia ChiuppesiDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-2921-5377
Felix WussowDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-7624-6734
Don J DiamondDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-3579-7083
City Of Hope National Medical Center · US

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
Project 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOFFMANN, ALEXANDER · 2017 to 2021
$11.2M
CMVPepVax to Protect HCT Recipients from Cytomegalovirus InfectionR01CA181045 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DIAMOND, DON J · 2014 to 2018
$3.6M
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivationR01CA266783 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Don J Diamond · 2023 to 2026
$2.6M
NCI NIH HHS P01 CA111412NCI NIH HHS P50 CA107399NCI NIH HHS R01 CA181045NCI NIH HHS R01 CA266783NIAID NIH HHS U19 AI128913
6 · The paper itself

Abstract

Human cytomegalovirus (CMV) is the most common infectious cause of complications post-transplantation, while a CMV vaccine for transplant recipients has yet to be licensed. Triplex, a multiantigen Modified Vaccinia Ankara (MVA)-vectored CMV vaccine candidate based on the immunodominant antigens phosphoprotein 65 (pp65) and immediate-early 1 and 2 (IE1/2), is in an advanced stage of clinical development. However, its limited genetic and expression stability restricts its potential for large-scale production. Using a recently developed fully synthetic MVA (sMVA) platform, we developed a new generation Triplex vaccine candidate, T10-F10, with different sequence modifications for enhanced vaccine stability. T10-F10 demonstrated genetic and expression stability during extensive virus passaging. In addition, we show that T10-F10 confers comparable immunogenicity to the original Triplex vaccine to elicit antigen-specific T cell responses in HLA-transgenic mice. These results demonstrate improvements in translational vaccine properties of an sMVA-based CMV vaccine candidate designed as a therapeutic treatment for transplant recipients.

Identifiers

PMID38555379
PMCPMC10981716
OpenAlexW4393334634

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.